<DOC>
	<DOC>NCT01238094</DOC>
	<brief_summary>The purpose of this study is to compare 2nd line XELIRI/FOLFIRI + simvastatin vs XELIRI/FOLFIRI + placebo.</brief_summary>
	<brief_title>Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer</brief_title>
	<detailed_description>To compare progression free survival of the standard second line chemotherapy (FOLFIRI, XELIRI) plus simvastatin in metastatic colorectal cancer patients. This trial is a placebo-controlled study.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1. Histologically documented colorectal adenocarcinoma (previously failed to oxaliplatin) 2. Age over 19 years old 3. Performance status (ECOG scale): 02 4. Measurable or evaluable disease 5. Adequate organ functions 6. Life expectancy â‰¥ 3 months 7. No history of statin treatment within the last 12 months 8. Patients should sign a written informed consent before study entry. 1. Tumor type other than adenocarcinoma 2. Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin, papillary thyroid carcinoma or prior malignancy treated more than 5 years ago without recurrence) 3. Adjuvant or neoadjuvant treatment for nonmetastatic (M0) disease is allowed if completed at least 6 months prior to initiation of study treatment. 4. Prior radiotherapy is permitted if it was not administered to target lesions selected for this study, unless progression of the selected target lesions within the radiation portal is documented, and provided it has been completed at least 4 weeks before randomization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>simvastatin</keyword>
	<keyword>second-line chemotherapy</keyword>
</DOC>